{
  "docId": "019de070-5095-745c-b54c-b78e5ae1b904",
  "docSlug": "0dc8a543e5d2136d106b59f85712c2a9",
  "documentTitle": "Taysha | IPO Presentation Deck | 66 slides",
  "authorId": "taysha",
  "authorName": "Taysha Gene Therapies",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 66,
  "pageCount": 66,
  "prevPage": 65,
  "nextPage": null,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Includes a diagram of the KCNQ2 protein structure and a visual representation of a gene therapy approach (AAV9 + hKCNQ2 + Intrathecal delivery).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-5095-745c-b54c-b78e5ae1b904/66",
  "deckHref": "/decks/019de070-5095-745c-b54c-b78e5ae1b904",
  "deckJsonHref": "/decks/019de070-5095-745c-b54c-b78e5ae1b904.json",
  "deckAnchorHref": "/decks/019de070-5095-745c-b54c-b78e5ae1b904#slide-66",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "image",
      "text": "AAV9 + hKCNQ2 + Intrathecal delivery",
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "118acdff-9b2e-46ff-a67d-72f768368ee5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "image",
      "text": "Diagram of KCNQ2 subunit structure",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fbda7a3-96f0-42cf-8d55-ef0ee060c367",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "KCNQ2 encodes voltage gated potassium channel subunit Kv7.2, a protein that complexes with other subunits to form potassium channels. The majority of KCNQ2 cases are due to loss of function (LOF) mutations. KCNQ2 is characterized by dramatic onset with multiple seizures occurring daily. Apnea and bradycardia are common, and a range of intellectual disabilities have been observed. The estimated prevalence of KCNQ2 is 17,000 patients in the US and EU.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4bafb659-0df9-40e5-bd77-efc68169cc00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Mutations in KCNQ2 result in severe neonatal epilepsy syndromes",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a0544ad-22ed-486a-99cf-870dd241c462",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "5475972a-9984-4f85-992e-1b94760bf152",
      "evidence": "list/bullet: KCNQ2 encodes voltage gated potassium channel subunit Kv7.2, a protein that complexes with other subunits to form potassium channels.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 66,
      "from": 31,
      "beatId": "a2d2f153-e121-48a0-8c8f-2d7d544ceb56",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The deck concludes with a call to action, presenting the company's plans for clinical and commercial development.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}